To only a minor degree I think. At the end of the day money is money and it's the milestones that will enable Neuren to carry out the critical PMS phase 3 with no serious financial stress. I mean in some ways it's more out there to ascribe a value to a drug still in development but then any pre approval loss making biotech would be worth nothing. I think a forward looking model based on expected revenues would just add them into the pile and spread it over the time expected to hit the next one. Yes at some point they cease but a business that hasn't evolved by then is in trouble and I think we all believe the true value of 2591 will be much clearer before then.
NEU Price at posting:
$12.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)